Press Release: Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre
Cannabis Law Report
JULY 13, 2022
The proposed phase I dosing study will aim to find the optimal microdose or low dose of psilocybin that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (
Let's personalize your content